What's happened
CVS Health has raised its 2026 adjusted earnings guidance to $7.90-$8.10 per share and expects revenue of at least $414 billion, citing improvements in its insurance and retail pharmacy segments. The update follows stronger quarterly results across all three business lines, with Aetna driving the uplift. The company also launches a CVS Health app program to expand access to Zepbound and Foundayo for eligible patients.
What's behind the headline?
Key angles
- CVS is raising full-year guidance as Aetna improves medical-cost management and revenue rises across segments. The 2026 outlook now sits at the higher end of its previous range, signaling sustained momentum.
- The company is expanding access to obesity treatments Zepbound and Foundayo through its app, potentially broadening payer participation and patient reach.
- Analysts’ expectations reflect a broader industry shift as insurers grapple with rising medical costs in Medicare Advantage and value-based care models.
What to watch
- Whether the higher guidance translates into sustained quarterly momentum or proves temporary as costs evolve.
- The impact of new obesity-treatment access on margins and member eligibility dynamics.
How we got here
CVS Health has been undergoing a turnaround aimed at cutting costs, closing underperforming stores, and streamlining Medicare Advantage plans. The results reflect progress across CVS’s three main segments—insurance, pharmacy, and health services—amid a challenging medical-cost environment.
Our analysis
CNBC reports CVS has lifted its full-year guidance to $7.90-$8.10 per share and revenue of at least $414 billion, driven by Aetna improvements and broad segment growth. The company notes a cautious year-ahead stance amid high medical costs, and announces a CVS Health app collaboration with Eli Lilly for Zepbound and Foundayo access. Bloomberg confirms the adjusted $7.90-$8.10 range with an emphasis on medical-cost management and premium efficiency. CNBC provides the quarter figures with EPS and revenue beats across all segments, highlighting a 6% premarket rise in CVS shares.
Go deeper
- What does this mean for CVS’s competitive position in health care?
- How might this expansion of weight-loss drugs affect costs and payer dynamics?
- What guarantees exist that the cost trend will stay favorable for the rest of the year?
More on these topics
-
CVS Health - Healthcare company
CVS Health is an American healthcare company that owns CVS Pharmacy, a retail pharmacy chain, CVS Caremark, a pharmacy benefits manager, Aetna, a health insurance provider, among many other brands. The company's headquarter is in Woonsocket, Rhode Island.
-
Wall Street - Street in New York City, New York
Wall Street is an eight-block-long street in the Financial District of Lower Manhattan in New York City. It runs between Broadway in the west to South Street and the East River in the east.
-
Aetna - Managed care company
Aetna Inc. is an American managed health care company that sells traditional and consumer directed health care insurance and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans, primarily thro